目的:探讨布南色林对早期利培酮治疗无应答首发精神分裂症患者神经递质表达的影响。方法:选取本院2022年1月至2022年12月期间住院治疗的120例早期行利培酮单药治疗无应答的首发精神分裂症患者作为研究对象,对照组和研究组各60例。对照...目的:探讨布南色林对早期利培酮治疗无应答首发精神分裂症患者神经递质表达的影响。方法:选取本院2022年1月至2022年12月期间住院治疗的120例早期行利培酮单药治疗无应答的首发精神分裂症患者作为研究对象,对照组和研究组各60例。对照组给予氯氮平治疗,研究组给予布南色林治疗,疗程3个月。比较两组患者阳性和阴性精神症状评定量表(positive and negative syndrome scale,PANSS)评分、生活质量综合评定问卷(generic quality of life inventory-74,GQOLI-74)评分、血清脑源性神经营养因子(brain derived neurotrophic factor,BDNF)浓度、血清S100β蛋白、神经元特异性烯醇化酶(neuron specific enolase,NSE)以及神经调节蛋白1(nerve regulatory protein 1,NRG1)水平,记录患者出现的药物不良反应。结果:治疗3个月后,两组PANSS评分均较治疗前有所下降,且研究组PANSS评分更低;两组躯体功能、社会功能、心理功能评分均高于治疗前,且研究组评分高于对照组,差异均有统计学意义(P均<0.05)。治疗3个月后,两组血清BDNF以及NRG1水平高于治疗前,且研究组高于对照组;两组S100β、NSE水平低于治疗前,且研究组低于对照组,差异均有统计学意义(P均<0.05)。两组均未发生严重不良反应事件。结论:布南色林可有效改善早期利培酮单药治疗无应答首发精神分裂症患者的症状,且能够合理调节患者神经递质表达,改善患者认知功能。展开更多
第二代(非典型)抗精神病药布南色林对多巴胺D2、D3受体和5-羟色胺2A(5 Hydroxytryptami ne 2A receptor,5-HT2A)受体均有较高亲和力,而对肾上腺素α1、5-HT2C、组胺H1、毒蕈碱M1和M3等受体亲和力较低。近10年临床研究显示布南色林不仅...第二代(非典型)抗精神病药布南色林对多巴胺D2、D3受体和5-羟色胺2A(5 Hydroxytryptami ne 2A receptor,5-HT2A)受体均有较高亲和力,而对肾上腺素α1、5-HT2C、组胺H1、毒蕈碱M1和M3等受体亲和力较低。近10年临床研究显示布南色林不仅对精神分裂症的阳性症状、阴性症状均有较好疗效,同时还具有抗焦虑抗抑郁作用,对患者的认知及其社会功能的改善疗效优越。展开更多
Background: Clozapine is the most efficacious among antipsychotics for patients with schizophrenia. Nevertheless, clozapine is not effective in more than about 50% of treatment refractory schizophrenia patients, and s...Background: Clozapine is the most efficacious among antipsychotics for patients with schizophrenia. Nevertheless, clozapine is not effective in more than about 50% of treatment refractory schizophrenia patients, and several pharmacological strategies are used to augment it. Several reviews including meta-analyses have been published, but the efficacy of augmentation therapy for clozapine-resistant patients is not adequately supported. Though there is a weak connection between the oral dose and plasma concentration of clozapine, there is no report of augmentation therapy considering the plasma concentration of clozapine. Blonanserin is reported to be effective in treatment of both positive and negative symptoms of schizophrenia and well tolerated. Methods: We obtained consent to evaluate clinical presentations and clozapine plasma concentrations at the Okayama Psychiatric Medical Center and had not identified the individual for ethical reasons. This is a case report. Results: This case fulfilled the diagnostic criteria of neuroleptic-induced dopamine supersensitivity psychosis. Monotherapy with blonanserin was not effective, but augmentation of blonanserin with clozapine was effective and well tolerated by a clozapine-resistant schizophrenia patient. Conclusion: Because clozapine may ameliorate dopamine supersensitivity psychosis, the addition of blonanserin to clozapine may be effective even if monotherapy with blonanserin was not.展开更多
文摘目的:探讨布南色林对早期利培酮治疗无应答首发精神分裂症患者神经递质表达的影响。方法:选取本院2022年1月至2022年12月期间住院治疗的120例早期行利培酮单药治疗无应答的首发精神分裂症患者作为研究对象,对照组和研究组各60例。对照组给予氯氮平治疗,研究组给予布南色林治疗,疗程3个月。比较两组患者阳性和阴性精神症状评定量表(positive and negative syndrome scale,PANSS)评分、生活质量综合评定问卷(generic quality of life inventory-74,GQOLI-74)评分、血清脑源性神经营养因子(brain derived neurotrophic factor,BDNF)浓度、血清S100β蛋白、神经元特异性烯醇化酶(neuron specific enolase,NSE)以及神经调节蛋白1(nerve regulatory protein 1,NRG1)水平,记录患者出现的药物不良反应。结果:治疗3个月后,两组PANSS评分均较治疗前有所下降,且研究组PANSS评分更低;两组躯体功能、社会功能、心理功能评分均高于治疗前,且研究组评分高于对照组,差异均有统计学意义(P均<0.05)。治疗3个月后,两组血清BDNF以及NRG1水平高于治疗前,且研究组高于对照组;两组S100β、NSE水平低于治疗前,且研究组低于对照组,差异均有统计学意义(P均<0.05)。两组均未发生严重不良反应事件。结论:布南色林可有效改善早期利培酮单药治疗无应答首发精神分裂症患者的症状,且能够合理调节患者神经递质表达,改善患者认知功能。
文摘第二代(非典型)抗精神病药布南色林对多巴胺D2、D3受体和5-羟色胺2A(5 Hydroxytryptami ne 2A receptor,5-HT2A)受体均有较高亲和力,而对肾上腺素α1、5-HT2C、组胺H1、毒蕈碱M1和M3等受体亲和力较低。近10年临床研究显示布南色林不仅对精神分裂症的阳性症状、阴性症状均有较好疗效,同时还具有抗焦虑抗抑郁作用,对患者的认知及其社会功能的改善疗效优越。
文摘Background: Clozapine is the most efficacious among antipsychotics for patients with schizophrenia. Nevertheless, clozapine is not effective in more than about 50% of treatment refractory schizophrenia patients, and several pharmacological strategies are used to augment it. Several reviews including meta-analyses have been published, but the efficacy of augmentation therapy for clozapine-resistant patients is not adequately supported. Though there is a weak connection between the oral dose and plasma concentration of clozapine, there is no report of augmentation therapy considering the plasma concentration of clozapine. Blonanserin is reported to be effective in treatment of both positive and negative symptoms of schizophrenia and well tolerated. Methods: We obtained consent to evaluate clinical presentations and clozapine plasma concentrations at the Okayama Psychiatric Medical Center and had not identified the individual for ethical reasons. This is a case report. Results: This case fulfilled the diagnostic criteria of neuroleptic-induced dopamine supersensitivity psychosis. Monotherapy with blonanserin was not effective, but augmentation of blonanserin with clozapine was effective and well tolerated by a clozapine-resistant schizophrenia patient. Conclusion: Because clozapine may ameliorate dopamine supersensitivity psychosis, the addition of blonanserin to clozapine may be effective even if monotherapy with blonanserin was not.
